Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. - sprookjes - yvandenbroek - TriplyDB

Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases.

Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases.

http://www.wikidata.org/entity/Q37403207

about

Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report Cellular mechanisms of bone remodeling Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone.Atypical femoral fracture due to chronic use of bisphosphonates: case report.Skeletal morbidity rates over time in patients with bone metastases from solid tumors reported in bone modifying agents randomised trials Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.Bisphosphonate-related osteonecrosis of the jaw: specificities.Strontium-89 therapy for the treatment of huge osseous metastases in prostate carcinoma: A case report Analysis of Pain and Interference Patterns With Brief Pain Inventory in Patients With Bone Metastases: A Confirmatory Study.Prevalence and Risk Factors of Atypical Femoral Fracture Bone Scintigraphic Feature in Patients Experiencing Bisphosphonate-Related Osteonecrosis of the Jaw

P2860

Q34284100-7700CED2-AEF0-4886-8394-A41A6E667BEB Q34486831-5621BA0C-C51C-4F0D-B6FF-054644AF0EE6 Q34525829-24BBD818-67FF-4F11-B793-8227FB912CF4 Q35637157-304565EC-D4D2-41F1-B2A4-94144B08042A Q36038290-53B06CE2-A604-42C5-A7D5-301C39B196A6 Q36491419-6DED26F3-D6FE-40CD-B315-00E733735A6B Q37687011-02F5B41E-9455-495D-8CCD-68BA1AD7F3B5 Q38493204-3B946F17-02C1-4D7F-B8AE-E011CB1F44D9 Q39232513-2887BEF7-C1A4-4F00-93D8-3E65FBBE16A8 Q47099969-BD864E09-7BDA-4C31-912A-EC96AF40DBDD Q56525024-B4834519-CDF9-4FE7-8A9F-1B73349DB1EB

P2860

Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases.

http://www.wikidata.org/entity/Q37403207

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bisphosphonates in oncology: e ...... patients with bone metastases.

@en

Bisphosphonates in oncology: e ...... patients with bone metastases.

@nl

type

label

Bisphosphonates in oncology: e ...... patients with bone metastases.

@en

Bisphosphonates in oncology: e ...... patients with bone metastases.

@nl

prefLabel

Bisphosphonates in oncology: e ...... patients with bone metastases.

@en

Bisphosphonates in oncology: e ...... patients with bone metastases.

@nl

P1433

Q37403207-1594F97B-F5B3-44F0-950C-41A0BD2BBC0C

P1476

Q37403207-74C65A2B-44D2-492C-BDBA-C2FE62A12362

P2093

Q37403207-89EE8DF3-9D37-4C86-AB15-A4142B57C081

P2860

Q37403207-00FB78EB-8AD6-4F62-B23F-6EF58D6626D0

Q37403207-031E2439-BA6F-4A9B-B73C-66ED01845547

Q37403207-0755AF12-D89B-49CF-8613-5BF323F37309

Q37403207-0EEE875F-9610-4834-9151-ACD7EEC4E1CB

Q37403207-1F40883C-879F-4C1E-B782-4BD410E4C044

Q37403207-25868666-0208-407E-92CA-25A72DE6C779

Q37403207-2A9A9F47-694A-4A02-80D8-C79A9F83F0AB

Q37403207-2C4B0C89-7864-4D1E-883B-B4671F5D360E

Q37403207-347CFD8D-D49F-4729-8F10-2B0FD4EBE121

Q37403207-36D62352-50F3-47C9-8F55-E2251865B4A3

P304

Q37403207-0A0E7005-4C3B-4F21-BA3C-EF5BA83B4D90

P31

Q37403207-6A8FD0C5-A525-459D-B397-0487BF47AFEA

P407

Q37403207-AFE1265B-3051-44F6-924B-EBE1B9BB7855

P478

Q37403207-F88C7B8F-D559-4FB7-B76A-5DEFCD24C0E3

P577

Q37403207-B413F7BF-505A-4E9C-BFAE-7DC4A48897A6

P698

Q37403207-1D9F18E4-5325-4EF0-9332-57A3F948EBC4

P932

Q37403207-A3378CF2-7A6C-4391-B52F-1A670BCBC3E5

P1433

Drug Design, Development and Therapy

P1476

Bisphosphonates in oncology: e ...... patients with bone metastases.

@en

P2093

Thomas J Polascik

http://www.w3.org/2001/XMLSchema#string

P2860

Bisphosphonates for advanced prostate cancer

Bisphosphonates for breast cancer

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

Clinical features of metastatic bone disease and risk of skeletal morbidity.

Zoledronic acid and clinical fractures and mortality after hip fracture.

P304

27-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19920919

http://www.w3.org/2001/XMLSchema#string

P932

2769231

http://www.w3.org/2001/XMLSchema#string